Comparative Study to Evaluate the Pharmacokinetics of BAT1806 vs Actemra® in Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

138

Participants

Timeline

Start Date

June 13, 2018

Primary Completion Date

July 17, 2019

Study Completion Date

July 17, 2019

Conditions

Rheumatoid Arthritis

Interventions

DRUG

BAT1806 injection

Each subject will receive single intravenous drip of 4 mg/kg BAT1806 Injection or Actemra® (EU-licensed and US-licensed).

Trial Locations (1)

The First Bethune Hospital of Jilin University, Changchun